NIH: Accelerating Medicine Partnership in Parkinson’s disease (AMP PD) unbiased proteomics biofluid analysis (U01 Clinical Trials Not Allowed)

The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from Accelerating Medicine Partnership in Parkinson’s disease (AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression.

The National Institute of Neurological Disorders and Stroke intends to commit up to $3,400,000 in FY19 to fund 1 award.

Due Date: May 29th, 2019

For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-028.html